MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- CAPLIN POINT (pharmaceuticals)
- Latest 8 Quarter Result
CAPLIN POINT Quarterly Results (CPNT)
Here are the latest quarterly results of CAPLIN POINT. For more details, see the CAPLIN POINT financial fact sheet and CAPLIN POINT share price and chart. For a sector overview, read our pharmaceuticals sector report.
CAPLIN POINT Quarterly Results
| No. of Mths Qtr. Ending |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 1,926 | 2,272 | 2,282 | 2,152 | 2,401 | 2,681 | 2,744 | 2,787 | |
| Other income | Rs m | 45 | 69 | 103 | 196 | 65 | 18 | 58 | 95 | |
| Turnover | Rs m | 1,970 | 2,341 | 2,386 | 2,349 | 2,466 | 2,699 | 2,802 | 2,882 | |
| Expenses | Rs m | 1,252 | 1,561 | 1,604 | 1,614 | 1,685 | 1,807 | 1,905 | 1,930 | |
| Gross profit | Rs m | 674 | 711 | 678 | 538 | 716 | 874 | 839 | 857 | |
| Depreciation | Rs m | 74 | 74 | 84 | 84 | 90 | 89 | 93 | 99 | |
| Interest | Rs m | 0 | 1 | 1 | 2 | 5 | 5 | 3 | 3 | |
| Profit before tax | Rs m | 645 | 705 | 696 | 649 | 686 | 798 | 802 | 850 | |
| Tax | Rs m | 144 | 133 | 107 | 160 | 141 | 170 | 141 | 171 | |
| Profit after tax | Rs m | 501 | 573 | 589 | 489 | 546 | 628 | 661 | 679 | |
| Gross profit margin | % | 35.0 | 31.3 | 29.7 | 25.0 | 29.8 | 32.6 | 30.6 | 30.7 | |
| Effective tax rate | % | 22.3 | 18.8 | 15.4 | 24.7 | 20.5 | 21.3 | 17.5 | 20.1 | |
| Net profit margin | % | 26.0 | 25.2 | 25.8 | 22.7 | 22.7 | 23.4 | 24.1 | 24.4 | |
| Diluted EPS | Rs | 6.6 | 7.6 | 7.8 | 6.5 | 7.2 | 8.3 | 8.7 | 9.0 | |
| Diluted EPS (TTM) | Rs | NA | NA | NA | 28.4 | 29.0 | 29.8 | 30.7 | 33.2 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: CAPLIN POINT 4QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: VANTA BIOSCIENCE SUNIL HEALTHCARE NECTAR LIFESCIENCE ALBERT DAVID SOURCE NATURAL FOODS
Compare CAPLIN POINT With: VANTA BIOSCIENCE SUNIL HEALTHCARE NECTAR LIFESCIENCE ALBERT DAVID SOURCE NATURAL FOODS
Today's Market
Sensex Ends 66 Points Lower; Bajaj Finance and Bajaj Finserv Among Top Nifty Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Views on news
CAPLIN POINT Announces Quarterly Results (4QFY21); Net Profit Up 39.0% (Quarterly Result Update)
Jul 9, 2021 | Updated on Jul 9, 2021For the quarter ended March 2021, CAPLIN POINT has posted a net profit of Rs 679 m (up 39.0% YoY). Sales on the other hand came in at Rs 3 bn (up 29.5% YoY). Read on for a complete analysis of CAPLIN POINT's quarterly results.
Windlas Biotech IPO to Hit the Market on 4 August. Key Points to Know (Views On News)
Jul 31, 2021Windlas Biotech IPO to open for subscription next week. Price band fixed at Rs 448-460.
Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates (Views On News)
Jul 30, 2021Here's a rundown on Sun Pharma's June quarter results.
Glenmark Life Sciences IPO Opens Tomorrow: Few Points to Know Before Applying (Views On News)
Jul 26, 2021All you need to know about the IPO of Glenmark Life Sciences.
Why Did Pharma Stocks Surge? (Views On News)
Jul 17, 2021A look into the factors contributing to the rally in pharma stocks.
More Views on NewsMost Popular
Make Startup Profits from Bluechip Stocks (Profit Hunter)
Jul 21, 2021A 166-bagger stock can deliver even more gains in this decade.
These Are the Best Stocks to Own (Fast Profits Daily)
Jul 22, 2021Find out what I think are the best kind on stocks to own in the market.
Cash the Crash in Gas Prices (Fast Profits Daily)
Jul 21, 2021Get ready to profit from the coming crash in the price of natural gas.
Electric 2-Wheelers: The Megatrend has Begun (Profit Hunter)
Jul 20, 2021The shift to electric 2-wheelers will be faster than expected.
A Trading Hack to Multiply Profits (Fast Profits Daily)
Jul 23, 2021Use this trading hack and get a big boost in your trading profits.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
CAPLIN POINT SHARE PRICE
Jul 30, 2021 (Close)
TRACK CAPLIN POINT
- Track your investment in CAPLIN POINT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CAPLIN POINT
CAPLIN POINT - MYLAN COMPARISON
COMPARE CAPLIN POINT WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.